U.S. Secondary Hyperoxaluria Drug Market, By Type (Reloxaliase, Thiazide Diuretics and Supplements), Drug Type (Prescription and Over the Counter), Population Type (Children and Adults), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
U.S. Secondary Hyperoxaluria Drug Market Analysis and Size
The U.S. secondary hyperoxaluria drug market is expected to witness significant growth during the forecast period. The increasing demand for disease-specific novel treatment, surge investment in R&D, low dietary awareness in society and loss of oxalobacter foreigners because of increased usage of antibiotics are projected to boost the secondary hyperoxaluria drug market growth. Such increasing prevalence has been the major driving factor, particularly among the urban population.
Data Bridge Market Research analyses a growth rate in the U.S. secondary hyperoxaluria drug market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
U.S. Secondary Hyperoxaluria Drug Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Reloxaliase, Thiazide Diuretics and Supplements), Drug Type (Prescription and Over the Counter), Population Type (Children and Adults), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Market Players Covered
|
Nestlé (Switzerland), GSK plc (U.K.), Bayer AG (Germany), Pharmavite (U.S.), Mission Pharmacal Company (U.S.), Oystershell (Belgium), Allena Pharmaceuticals (U.S.), OxThera (Sweden), Renew Life (U.S.), Synlogic (U.K.), Amway Corp (U.S.), Infinitus (China), Nature’s Bounty (Bohemia), Now Foods (Canada), Solgar Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Secondary hyperoxaluria drugs are used to regulate the increased dietary ingestion of oxalate and precursors of oxalate in the intestinal system. It affects the different organs and tissues by absorption of high oxalate concentration. The disease can lead to chronic kidney disease, recurrent kidney stones, nephrocalcinosis, urinary tract infections, and end-stage renal disease.
Secondary Hyperoxaluria Drug Market Dynamics
Drivers
- High demand of healthcare segment
The home healthcare segment is boosting the secondary hyperoxaluria drug market as most of the drugs are taken at home by the patients without the need for medical professionals.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the secondary hyperoxaluria drug market. To encourage researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives
- Increasing demand for retail pharmacies
The rise in the number of drugs being delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified healthcare professionals who are unable to treat these patients with appropriate treatments could curb the growth of the U.S. secondary hyperoxaluria drug market over a forecast period.
- High cost
The huge expenditure associated with the high-end drugs hamper the market growth. Several type of thiazide diuretics and supplements are becoming of increasing cost and thus is impeding the growth of the market.
This U.S. secondary hyperoxaluria drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the U.S. secondary hyperoxaluria drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
U.S. Secondary Hyperoxaluria Drug Market Scope
The U.S. secondary hyperoxaluria drug market is segmented on the basis of type, drug type, population type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Reloxaliase
- Thiazide Diuretics
- Supplements
Drug Type
- Prescription
- Over the Counter
Population Type
- Children
- Adults
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Competitive Landscape and U.S. Secondary Hyperoxaluria Drug Market Share Analysis
The U.S. secondary hyperoxaluria drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to U.S. secondary hyperoxaluria drug market
Key players operating in the U.S. secondary hyperoxaluria drug market include:
- Nestlé (Switzerland), GSK plc (U.K.)
- Bayer AG (Germany)
- Pharmavite (U.S.)
- Mission Pharmacal Company (U.S.)
- Oystershell (Belgium)
- Allena Pharmaceuticals (U.S.)
- OxThera (Sweden)
- Renew Life (U.S.)
- Synlogic (U.K.)
- Amway Corp (U.S.)
- Infinitus (China))
- Now Foods (Canada)
- Solgar Inc. (U.S.)
SKU-